Abbott Launches Latest Insertable Cardiac Monitor For Irregular Heart Rhythms - Abbott Laboratories (NYSE:ABT)

Abbott Laboratories ABT launched the Jot Dx, its latest insertable cardiac monitor (ICM), in the U.S.
The technology allows for remote detection and improved diagnostic accuracy of cardiac arrhythmias in patients.
Jot Dx offers clinicians and hospitals control of managing the flow of information through a feature that allows the viewing of abnormal heart rhythm data and provides the opportunity to simplify which irregular heart rhythms are recorded with a “key episodes” feature, according to a news release.
Data presented at Heart Rhythm 2021 demonstrated that Jot Dx provides a 63% data reduction burden.
Jot Dx ICM continuously monitors patient cardiac rhythms and connects directly to myMerlin, a downloadable mobile app that transmits real-time data to both the clinician and patient.
Price Action: ABT shares are down 0.12% at $121.24 during the market session on the last check Friday.